Form 4: Relmada Therapeutics Director John Glasspool Granted 100,000 Stock Options
Insider Transaction Report
Relmada Therapeutics Director John Glasspool was granted 100,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.
Summary
- John Glasspool, a Director of Relmada Therapeutics, Inc. (RLMD), acquired 100,000 stock options.
- The stock options have an exercise price of $0.67 per share.
- The options begin vesting on September 26, 2025, in 16 equal quarterly installments.
- The expiration date for these stock options is June 26, 2035.
- Following this transaction, John Glasspool directly beneficially owns 100,000 derivative securities.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with the long-term performance of the company, indicating a commitment to the company's future.
Positives
- The grant of stock options to a director aligns management's interests with long-term shareholder value.
Future Outlook
The stock options granted to the director will vest over a period of 16 equal quarterly installments, commencing on September 26, 2025, indicating a long-term incentive structure for the director.
Industry Context
Insider stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term company performance and shareholder interests.
Comparison to Industry Standards
- The grant of stock options to directors is a standard practice across various industries, including biotechnology, to incentivize long-term commitment and performance.
- The exercise price of $0.67 is specific to the company's stock price at the time of grant and would require comparison to peer company option grants at similar market valuations for a detailed assessment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Application | The grant of stock options is part of the company's compensation policy for directors, reflecting standard corporate governance practices for incentivizing leadership. | 06/26/2025 | Aligns director's financial interests with long-term company performance and shareholder value. |
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of the director's interests with shareholder value through long-term equity incentives.
Next Steps
- Continued vesting of the 100,000 stock options in 16 equal quarterly installments commencing September 26, 2025.
Key Dates
| Date | Description |
|---|---|
| 06/26/2025 | Date of earliest transaction, when 100,000 stock options were acquired. |
| 09/26/2025 | Date when the stock options begin vesting in 16 equal quarterly installments. |
| 06/30/2025 | Date the Form 4 was signed and filed. |
| 06/26/2035 | Expiration date of the stock options. |
Recommendation
holdKeywords
Relmada Therapeutics, RLMD, John Glasspool, SEC Form 4, Stock Options, Director Compensation, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.